Real-world experience of the clinical effectiveness of omalizumab use in Qatar – a study protocol

Omalizumab (XOLAIR®) is a recombinant DNA-derived humanized IgG1κ monoclonal antibody that binds to IgE and was first introduced in Qatar in 2009. Omalizumab is used to treat moderate-to-severe allergic asthma (SAA), chronic idiopathic urticaria (CIU), and chronic rhinosinusitis with nasal polyposis...

Descripción completa

Detalles Bibliográficos
Autores principales: Purayil, Saleema, Mobayed, Hassan, Al-Nesf, Maryam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: HBKU Press 2022
Materias:
First Qatar Allergy Conference
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284588/
https://www.ncbi.nlm.nih.gov/pubmed/35909407
http://dx.doi.org/10.5339/qmj.2022.fqac.3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284588/
https://www.ncbi.nlm.nih.gov/pubmed/35909407
http://dx.doi.org/10.5339/qmj.2022.fqac.3

Ejemplares similares